Metraipolis › archive › dc_73753ddbdf14

Real-world effectiveness of SGLT2 inhibitors in patients with HF and ESKD: a multicenter cohort study — Europe PMC PMID:41623612

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41623612
DOI
10.3389/fcvm.2026.1652863
License (as archived)
solo-consultazione
Archived
2026-11-06T18:05:36.093Z
SHA-256 of the archived text
ccc05a5dec5335c8395dc1e966317ea178516825e402c55dcaacc2b75dc1f4de
Stable URL of this page
https://metraipolis.com/documento/dc_73753ddbdf14

How to cite

Real-world effectiveness of SGLT2 inhibitors in patients with HF and ESKD: a multicenter cohort study — Europe PMC PMID:41623612 — Europe PMC (en), https://europepmc.org/article/MED/41623612 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_73753ddbdf14 (Metraipolis archive dc_73753ddbdf14, sha256 ccc05a5dec5335c8395dc1e966317ea178516825e402c55dcaacc2b75dc1f4de)
BibTeX
@misc{dc73753ddbdf14,
  title = {Real-world effectiveness of SGLT2 inhibitors in patients with HF and ESKD: a multicenter cohort study — Europe PMC PMID:41623612},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41623612},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_73753ddbdf14; sha256 ccc05a5dec5335c8395dc1e966317ea178516825e402c55dcaacc2b75dc1f4de},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41623612. Agents can read the archived copy with the MCP tool read_document.